Live symbol workspace

JNJ market intelligence

Chart, AI analysis, key levels, technical analysis, sentiment, and market news are grouped so the next action is always visible.

Current $243.04

Trend Flat

Sentiment Neutral

{# Only render the live technical grid when the AI analysis carries real, non-placeholder data. Sentinel payloads (data_status error/collecting, current_price 0) are handled by the Asset Intelligence Dossier below, which degrades to a calm branded empty state instead of "0%" widgets. #}

Detailed Market Analysis

Key Levels

Support

$230.89

Resistance

$255.19

Volume & Momentum

Volume

Normal

1.0x avg

Momentum

0%

Weak

Technical Analysis

HOLD

Entry $243.04

Stop $230.89

Target $255.19

RSI: 50 | Current: $243.04

Market Sentiment

50

Neutral

Stock Metrics

Daily Vol

0%

VIX Est

20

Weekly

0%

Asset Intelligence Dossier

Over the last 30 days, AI sentiment for JNJ skewed bullish (3 of 6 scored calls).

Provider track record

Not enough scored provider calls yet for this asset.

Confidence trend

35%

▼ 6.5 pts vs previous week

Avg confidence across 19 calls in the last 7 days

What sources say

Bullish 3 articles

Is Johnson & Johnson (JNJ) One of the Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026?

S&P 500, Nasdaq boosted by chips to record closing highs

Frothy, but not like 1999: This new valuation indicator has stocks beating inflation

Bearish 2 articles

US Ebola Aid Plummets 99% Since Last Outbreak

3 Healthcare Stocks with Open Questions

Neutral 1 article

Congo Faces Surge in Ebola Cases as Key Medical Tools Run Short

Insider Trading

Refreshing insider trades from FinViz…

Technical Signals

Refreshing technical signals from FinViz…

JNJ News Intelligence (14 articles)

AI-curated news influencing JNJ price, sentiment, and trend

Explore All JNJ News with AI Analysis

Economy

1 month ago

3 Vanguard ETFs Crushing the S&P 500 in 2026

The rotation we've seen within U.S. equities this year has created a new class of winners outside of tech and …

Impact on JNJ: The outperformance of these Vanguard ETFs may lead to increased capital flows …

Three Vanguard ETFs are outperforming the S&P 500 in 2026, indicating a shift in market … High (70%)

View full analysis →

Yahoo Finance 70% confidence

Economy

1 month, 1 week ago

Johnson & Johnson (JNJ) is Gaining from Its Strong Innovative Medicine Growth

Mar Vista Investment Partners, LLC, an investment management company, released its “Mar Vista U.S. Quality Strategy” first-quarter 2026 investor letter. …

Impact on JNJ: Neutral market sentiment indicated

FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence. High (94%)

View full analysis →

Yahoo Finance 94% confidence

Economy

1 month, 1 week ago

Better Buy Right Now: Johnson & Johnson Vs. Pfizer

The choice is based on more than just the dividend payout.

Impact on JNJ: Insufficient data to determine direct market consequences, but a positive or negative …

The article compares Johnson & Johnson and Pfizer as investment options, considering factors beyond dividend … Low (20%)

View full analysis →

Yahoo Finance 20% confidence

Economy

1 month, 1 week ago

Japan to Work With Asian Nations to Ease Oil Bottleneck: Akazawa

Japan will work closely with Asian countries where essential petroleum-based products including medical equipment are produced, economy minister Ryosei Akazawa …

Impact on JNJ: The news may lead to a decrease in oil prices and a …

Japan's economy minister announced plans to collaborate with Asian nations to alleviate oil supply chain … High (70%)

View full analysis →

Bloomberg 70% confidence

Economy

2 months ago

Why AbbVie Stock Looks Like a Dirt Cheap Buy Right Now

AbbVie has strong financials, a great dividend, and its stock trades at a modest valuation.

Impact on JNJ: AbbVie's (ABBV) undervaluation could lead to a price increase, potentially driving the …

AbbVie's strong financials, attractive dividend, and modest valuation make its stock appear undervalued, presenting a … High (70%)

View full analysis →

Yahoo Finance 70% confidence

Stocks

2 months ago

Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trial

Pharmaceutical giant Pfizer and French partner Valneva on Monday said they planned to seek regulatory approval for a Lyme disease …

Impact on JNJ: The announcement is likely to have a positive impact on Pfizer's (PFE) …

Pfizer and Valneva plan to seek regulatory approval for a Lyme disease vaccine after a … High (80%)

View full analysis →

MarketWatch 80% confidence